A Perspective on the Use of FVIII Concentrates and Cryoprecipitate Prophylactically in Surgery or Therapeutically in Severe Bleeds in Patients with von Willebrand Disease Unresponsive to DDAVP: Results of an International Survey

Summary

An international registry was established by the Subcommittee on von Willebrand Factor of the SSC/ISTH on the treatment of patients with types of von Willebrand disease (vWd) unresponsive to DDAVP infusion. Data was collected on 76 surgical events in 64 patients from 19 treatment centers. Thirty-three non-mucosal, 12 mucosal, 10 orthopedic and 21 dental procedures were reported. In the 76 surgical events, 14 cases prophylactically received cryoprecipitate while 62 received factor VIII (FVIII) concentrate. Surgical hemostasis was reported as satisfactory, good, or excellent in 75 of the 76 cases. Post-infusion bleeding times were measured in only three of 14 surgical events treated with cryoprecipitate. All three cases had a reduction but not correction of the bleeding time. The post-infusion bleeding time was measured in 27 of 62 cases in which FVIII concentrates were used. The bleeding time was normalized in 15, reduced but not normalized in eight, and not changed from baseline in four. Data was also collected from 16 treatment centers on 50 serious bleeding events in 35 patients. These included 19 gastrointestinal, 15 other mucosal, four central nervous system, seven orthopedic, and five other bleeds. Eleven cases received cryoprecipitate and 39 received FVIII concentrate as primary therapy. The efficacy of treatment was considered good or excellent in 49 of 50 cases. Post-infusion bleeding times were measured in only 15 of the 50 reported bleeding events. The post-infusion bleeding time was normalized in six, decreased but not normalized in eight, and not changed from baseline in one. In this retrospective survey, FVIII concentrates were subjectively as efficacious as cryoprecipitate in both the surgical setting and for the treatment of severe bleeds in patients with types of vWd unresponsive to DDAVP. Since the bleeding time was monitored during therapy in only a minority of these cases, a definitive relationship between the efficacy of therapy and normalization or reduction of the bleeding time in these two clinical settings cannot be established from this study. A prospective study on the use of FVIII and/or vWf concentrates in these clinical settings is necessary to address this issue.

• References

• 1 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 454-459
• 2 Batlle J, Lopez-Femandez MF. Von Willebrand disease in Spain and Portugal. Thromb Haemost 1989; 62: 223 (abstract)
• 3 Nilsson IM. Von Willebrand’s disease from 1926-1983. Scand J Haematol (Suppl) 1984; 33: 21-43
• 4 Colvin BT, O’Callaghan U, Thomas N. A survey of von Willebrand’s disease in North London. Research in Clinical Laboratories 1986; 16: 236 (abstract)
• 5 Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for Desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Rev 1991; 5: 155-161
• 6 Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-525
• 7 Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992; 62: 193-199
• 8 Lethagen S, Bemtorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand’s disease type III. Ann Hematol 1992; 65: 2539
• 9 Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M. Clinical and biological evaluation in von Willebrand’sdisease of a von Willebrand factor concentrate with low factor VIII activity. BrJ Haematol 1992; 80: 214-221
• 10 Mannucci PM, Moia M, Altieri D, Monteagudo J, Castillo R. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 1987; 25: 55-65
• 11 Cornu P, Larrieu MJ, Caen J, Bernard J. Transfusion studies in von Willebrand’s disease: Effect on bleeding time and factor VIII. Br J Haemotol 1963; 9: 189-202
• 12 Biggs R, Matthews JM. The treatment of haemorrhage in von Willebrand’s disease and the blood level of factor VIII (AHG). Br J Haemotol 1963; 9: 203-214
• 13 Nilsson IM, Magnusson S, Borchgrevink C. The Duke and Ivy methods for determination of the bleeding time. Thromb Diath Haemorrh 1963; 10: 223-224
• 14 Larrieu MJ, Caen JP, Meyer DO, Vainer H, Sultan Y, Bernard J. Congenital bleeding disorders with long bleeding time and normal platelet count. Am J Med 1968; 45: 354-372
• 15 Perkins HA. Correction of the hemostatic defects in von Willebrand’s disease. Blood 1967; 30: 375-380
• 16 Green D, Potter EV. Failure of AHF concentrate to control bleeding in von Willebrand’s disease. Am J Med 1976; 60: 357-360
• 17 Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities JAMA 1976; 236: 2770-2772
• 18 Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickies FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb Haemost 1994; 71: 173-179